In this additional nationwide questionnaire‐based study, patients who underwent allo‐HCT for AML with BCR::ABL1 showed better OS, LFS, and NRM rates than those for MPAL with BCR::ABL1. The gene discussed is BCR; the disease is acute myeloid leukemia.